Jad Chahoud, Chief Scientific and Innovation Officer at Orlando Health Cancer Institute, shared a post on LinkedIn:
“The Right Timing matters even in immunotherapy!
A new Nature Medicine study in lung cancer shows that patients receiving IO + chemotherapy earlier in the day had better outcomes than those treated later.
- This likely reflects circadian immune biology.
- The immune system is time-dependent.
- Drug synergy isn’t just what we give, but when we give it.
Big takeaway: Chronotherapy may be one of the simplest, fastest ways to improve outcomes without new drugs or added toxicity.
A free frontier in precision oncology may be the. Pending phase 3 validation in United States.”
Title: Time-of-day immunochemotherapy in non small cell lung cancer: a randomized phase 3 trial
Authors: Zhe Huang, Liang Zeng, Zhaohui Ruan, Qun Zeng, Huan Yan, Wenjuan Jiang, Yi Xiong, Chunhua Zhou, Haiyan Yang, Li Liu, Jiacheng Dai, Nachuan Zou, Shidong Xu, Ya Wang, Zhan Wang, Jun Deng, Xue Chen, Jing Wang, Hua Xiang, Xiaomei Li, Boris Duchemann, Guoqiang Chen, Yang Xia, Tony Mok, Christoph Scheiermann, Francis Lévi, Nong Yang, Yongchang Zhang
Read The Full Article on Nature Medicine
More posts featuring Jad Chahoud on OncoDaily.